What’s the Problem?
This recall affects 1 lot of Metformin Hydrochloride Extended-Release Tablets USP, 500 mg, 1000 count bottles and 1 lot of Metformin Hydrochloride Extended-Release Tablets USP, 750 mg, 100 count bottles, according to the U.S. Food & Drug Administration (FDA). These products were manufactured by Beximco Pharmaceuticals Limited, Dhaka, Bangladesh in June 2019, for U.S. distribution by Bayshore Pharmaceuticals, LLC, of Short Hills, New Jersey.
Bayshore issued the recall after the FDA notified it that lot number 18657 of its Metformin Hydrochloride Extended-Release Tablets, USP 750 mg was tested and showed results for NDMA levels in excess of the Acceptable Daily Intake Limit (ADI).
“NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests,” FDA said. “NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.”
If you were prescribed any metformin that is affected by this recall, you should consult your physician for advise regarding an alternative treatment. “It could be dangerous for patients with this serious condition to stop taking their Metformin without first talking to their healthcare professionals,” FDA said.
This recall began on August 19, 2020.
Do I Have a Bayshore Metformin Recall Lawsuit?
The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Bayshore Metformin Recall Lawsuits. We are handling individual litigation nationwide and currently accepting new injury and death cases in all 50 states.
If you or a loved one was injured by metformin, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.